Context Therapeutics Inc (CNTX NASDAQ) stock market data APIs
$1.0679
0.05(4.7%)
as of November 6, 2025
Try our APIs with
free plan!
Context Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Prev. Close
1.0679
Open
1.1203
High
1.1471
Low
1.0381
52 wk Range
0.49-2.1
Market Cap
101 M
Shares Outstanding
89 704 K
EPS
0
Beta
1.944
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Context Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Context Therapeutics Inc data using free add-ons & libraries
Get Context Therapeutics Inc Fundamental Data
Context Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -38 285 488
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: -0.087
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Context Therapeutics Inc News
New
Context Therapeutics GAAP EPS of -$0.10 misses by $0.01
* Context Therapeutics press release [https://seekingalpha.com/pr/20295545-context-therapeutics-reports-third-quarter-2025-operating-and-financial-results] (CNTX [https://seekingalpha.com/symbol/CNT...
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
Ongoing Phase 1 trial of CTIM-76 (CLDN6 x CD3) demonstrates encouraging antitumor activity and safety Ongoing Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels Cash and cash equi...
Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer
Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Ph...
Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer
Step Pharma Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will acce...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
